Shattuck Labs (NASDAQ:STTK – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.
Risk and Volatility
Shattuck Labs has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.
Profitability
This table compares Shattuck Labs and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shattuck Labs | N/A | -43.57% | -40.90% |
| Aurinia Pharmaceuticals | 100.84% | 26.11% | 19.89% |
Valuation & Earnings
This table compares Shattuck Labs and Aurinia Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shattuck Labs | $1.00 million | 550.98 | -$48.81 million | ($0.51) | -10.76 |
| Aurinia Pharmaceuticals | $283.05 million | 7.93 | $287.20 million | $2.29 | 7.36 |
Aurinia Pharmaceuticals has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for Shattuck Labs and Aurinia Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shattuck Labs | 1 | 0 | 9 | 3 | 3.08 |
| Aurinia Pharmaceuticals | 0 | 3 | 3 | 1 | 2.71 |
Shattuck Labs currently has a consensus price target of $13.70, suggesting a potential upside of 149.54%. Aurinia Pharmaceuticals has a consensus price target of $17.75, suggesting a potential upside of 5.28%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, research analysts plainly believe Shattuck Labs is more favorable than Aurinia Pharmaceuticals.
Insider & Institutional Ownership
58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Aurinia Pharmaceuticals beats Shattuck Labs on 9 of the 15 factors compared between the two stocks.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
